These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12237296)

  • 1. Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design.
    Joyce JG; Hurni WM; Bogusky MJ; Garsky VM; Liang X; Citron MP; Danzeisen RC; Miller MD; Shiver JW; Keller PM
    J Biol Chem; 2002 Nov; 277(48):45811-20. PubMed ID: 12237296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.
    McGaughey GB; Citron M; Danzeisen RC; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller M; Shiver J; Bogusky MJ
    Biochemistry; 2003 Mar; 42(11):3214-23. PubMed ID: 12641452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
    Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW
    J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress towards the development of a HIV-1 gp41-directed vaccine.
    McGaughey GB; Barbato G; Bianchi E; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller MD; Pessi A; Shiver JW; Bogusky MJ
    Curr HIV Res; 2004 Apr; 2(2):193-204. PubMed ID: 15078183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
    Neurath AR; Strick N; Lin K; Jiang S
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):687-96. PubMed ID: 7576928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design.
    Serrano S; Araujo A; Apellániz B; Bryson S; Carravilla P; de la Arada I; Huarte N; Rujas E; Pai EF; Arrondo JLR; Domene C; Jiménez MA; Nieva JL
    J Biol Chem; 2014 Mar; 289(10):6565-6580. PubMed ID: 24429284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
    Julien JP; Bryson S; Nieva JL; Pai EF
    J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.
    Parker CE; Deterding LJ; Hager-Braun C; Binley JM; Schülke N; Katinger H; Moore JP; Tomer KB
    J Virol; 2001 Nov; 75(22):10906-11. PubMed ID: 11602730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes.
    Lapelosa M; Gallicchio E; Arnold GF; Arnold E; Levy RM
    J Mol Biol; 2009 Jan; 385(2):675-91. PubMed ID: 19026659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
    Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
    Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178.
    Wexler-Cohen Y; Johnson BT; Puri A; Blumenthal R; Shai Y
    J Biol Chem; 2006 Apr; 281(14):9005-10. PubMed ID: 16455666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine.
    Liao M; Lu Y; Xiao Y; Dierich MP; Chen Y
    Peptides; 2000 Apr; 21(4):463-8. PubMed ID: 10822100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2F5 epitope is helical in the HIV-1 entry inhibitor T-20.
    Biron Z; Khare S; Quadt SR; Hayek Y; Naider F; Anglister J
    Biochemistry; 2005 Oct; 44(41):13602-11. PubMed ID: 16216084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41.
    Dong XN; Xiao Y; Chen YH
    Immunol Lett; 2001 Jan; 75(2):149-52. PubMed ID: 11137140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41.
    Gorny MK; Zolla-Pazner S
    J Virol; 2000 Jul; 74(13):6186-92. PubMed ID: 10846104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, conformation, and immunogenicity of monosaccharide-centered multivalent HIV-1 gp41 peptides containing the sequence of DP178.
    Ni J; Powell R; Baskakov IV; DeVico A; Lewis GK; Wang LX
    Bioorg Med Chem; 2004 Jun; 12(12):3141-8. PubMed ID: 15158782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5.
    de la Arada I; Julien JP; de la Torre BG; Huarte N; Andreu D; Pai EF; Arrondo JL; Nieva JL
    J Phys Chem B; 2009 Oct; 113(41):13626-37. PubMed ID: 19754136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
    Phogat S; Svehla K; Tang M; Spadaccini A; Muller J; Mascola J; Berkower I; Wyatt R
    Virology; 2008 Mar; 373(1):72-84. PubMed ID: 18155743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple antigen peptide mimetics containing gp41 membrane-proximal external region elicit broad neutralizing antibodies against human immunodeficiency virus type 1 in guinea pigs.
    Zhang L; Miao L; Gong X; Zhang H; Yang L; Shi Y; Kong W; Jiang C; Shan Y
    J Pept Sci; 2013 Aug; 19(8):491-8. PubMed ID: 23794478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.